Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Esomeprazol, Nexium; Belgium: Nexiam; Bulgaria: Nexium; Cyprus: Nexium; Czech Republic: Esomeprazol, Nexium; Denmark: Esomeprazol, Inexium, Nexium; Estonia: Nexium, Nexmezol; Finland: Nexium; France: Inexium; Germany: Nexium, Refexxin; Greece: Nexium; Hungary: Esomeprazol, Nexium; Ireland: Emazole, Nexium; Italy: Axagon, Esopral, Lucen, Nexium; Latvia: Nexium, Nexmezol; Malta: Nexium; Netherlands: Esomeprazol, Nexium; Poland: Nexium; Portugal: Esomeprazol, Nexium; Romania: Esomeprazol, Nexium; Slovakia: Nexium; Slovenia: Nexium, Nilar; Spain: Axiago, Nexium; Sweden: Axagon, Axiago, Cativa, Esopral, Inexium, Nexiam, Nexium, Reffexxin; UK: Nexium.

North America

Canada: Nexium; USA: Nexium.

Latin America

Argentina: Esomax, Esoprazol, Nexium; Brazil: Nexium; Mexico: Nexium.

Drug combinations

Esomeprazole and Naproxen


Esomeprazole Magnesium: C~34~H~36~MgN~6~O~6~S~2~ 3H~2~O. Mw: 767.17. (1) 1H-Benzimidazole,5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt, trihydrate; (2) 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate. CAS-217087-09-7 (1999).

Esomeprazole Sodium: C~17~H~19~N~3~NaO~3~S. Mw: 368.41. 1H-Benzimidazole, 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt. CAS-161796-78-7 (2003).

Pharmacologic Category

Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors. Substituted Benzimidazole. (ATC-Code: A02BC05).

Mechanism of action

Proton pump inhibitor suppresses gastric acid secretion by inhibition of the H^+^/K^+^-ATPase in the gastric parietal cell.

Therapeutic use

Short-term (4-8 weeks) treatment of erosive esophagitis. Treatment of symptomatic gastroesophageal reflux disease (GERD). As part of a multidrug regimen for Helicobacter pylori eradication in duodenal ulcer disease (active or history of same within past 5 years). Prevention of gastric ulcers in patients at risk (age ≥60 years and/or history of gastric ulcer) associated with continuous NSAID therapy. Long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome. Treatment of non-erosive reflux disease (NERD). I.V. short-term (≤10 days) treatment of GERD when oral therapy is not possible or appropriate.

Pregnancy and lactiation implications

There are no adequate, well-controlled studies in pregnant women. Congenital abnormalities reported sporadically following omeprazole use during pregnancy. Use not recommended if breast-feeding.

Unlabeled use


Hypersensitivity to esomeprazole, substituted benzimidazoles (e.g. lansoprazole, omeprazole, pantoprazole, rabeprazole), or any component of the formulation.

Warnings and precautions

Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with esomeprazole. No reports of enterochromaffin-like cell carcinoids, dysplasia, or neoplasia. Relief of symptoms does not preclude presence of gastric malignancy.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart